Issue of equity and total voting rights

RNS Number : 2836X

Tissue Regenix Group PLC

09 January 2014

 



Tissue Regenix Group plc

Issue of equity and total voting rights

YORK, 9 January 2014 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the international regenerative medical devices company, announces that it has today issued and allotted 635,674 ordinary shares of 0.5p each in the Company, following an exercise of options which were granted under the Company's Enterprise Management Incentive scheme.

The 635,674 new ordinary shares will rank pari passu with the existing ordinary shares and application will be made for these new ordinary shares to be admitted to trading on AIM. It is expected that Admission will occur at 8:00 a.m. on Tuesday 14 January 2014.

Total Voting Rights

Following the issue of the 635,674 new ordinary shares, the Company will have a total of 653,460,693 ordinary shares of 0.5p each in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

ENDS

For Further Information

Tissue Regenix Group Plc:                                                           [phone]

Antony Odell

Ian Jefferson

Jefferies International Ltd:                                                         [phone]

Simon Hardy

Harry Nicholas

Newgate Communications:                                                        [phone]

Alistair Kellie                                                                                   

Andrew Jones                                                                  

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

IOEEAFFNEELLEFF